Suzanne Vormer-Bonne

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Doxorubicin (DOX) is a potent antitumor agent for different types of cancer, but the cumulative, dose-related cardiotoxicity limits its clinical use. The incidence of abnormal cardiac function after treatment with DOX appears to increase with time. Therefore, late cardiotoxicity is—especially in young surviving patients—a major concern. The aim of this(More)
  • 1